Creating antibodies to fight Pseudomonas aeruginosa infections
Official title: Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections
Funded at West Virginia University · NIH-10999730 · Data updated 2026-11-12
This study is working on creating new treatments using special antibodies to help fight tough infections caused by a bacteria called Pseudomonas aeruginosa, especially in people with sepsis, so that patients can have better options when antibiotics don't work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $741,917 |
| NIH project number | 1R01AI180050-01A1 |
| Project ID | NIH-10999730 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with severe infections caused by multidrug-resistant Pseudomonas aeruginosa, particularly those experiencing sepsis.
✕Less likely to help
Patients with infections caused by non-Pseudomonas aeruginosa bacteria or those who are not experiencing severe infections may not benefit from this research.
What this research studies
This research focuses on developing therapeutic antibodies to combat multidrug-resistant Pseudomonas aeruginosa infections, particularly in cases of sepsis. The approach involves creating a cocktail of antibodies that specifically target the lipopolysaccharide of the bacteria, which is crucial for its survival and virulence. The study will assess the effectiveness of these antibodies in laboratory settings and in animal models to determine their potential in treating infections. Patients may benefit from new treatment options that are effective against antibiotic-resistant strains of this dangerous pathogen.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients suffering from severe infections caused by antibiotic-resistant Pseudomonas aeruginosa.
How similar studies have gone: Previous research has shown promise in using antibody therapies for bacterial infections, indicating potential success for this novel approach.
Where this research is happening
-
West Virginia University
Morgantown, United States Active
Researchers
- Principal investigator: Barbier, Mariette — West Virginia University
- Study coordinator: Barbier, Mariette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.